ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer.

ABSTRACT:

Introduction

To investigate the molecular mechanisms underlying enzalutamide resistance in castration-resistant prostate cancer (CRPC) and explore potential therapeutic strategies to overcome resistance.

Methods

We conducted comprehensive bioinformatic analysis using LNCaP/enzalutamide-resistant cells to identify key pathways associated with resistance. Functional validation was performed through targeted inhibition of the elongation of very-long chain fatty acid protein 2 (ELOVL2), followed by assays to assess cancer cell proliferation and enzalutamide sensitivity. Mechanistic studies were conducted to evaluate the impact of ELOVL2 on the ubiquitin-proteasome system and AR signaling pathways.

Results

Bioinformatic analysis revealed that activation of fatty acid metab

SUBMITTER: Cen J 

PROVIDER: S-EPMC12183063 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature